R ecombinant tissue plasminogen activator (r-tPA) is a highly effective treatment for acute ischemic stroke if patients can be treated within 4.5 hours.
occurred (4.6%; 95% confidence interval [CI] , 0.9-12.9); 40% had complete recanalization within 2 hours (compared with 18% of historical controls treated with r-tPA alone), and 36% of those assessed at 90 days had an excellent outcome (0-1 modified Rankin Scale score [mRS] ).
These encouraging results prompted us to undertake an exploratory, phase IIb, randomized trial, with similar inclusion/exclusion criteria to test the same dose of argatroban in the single-arm study and a higher dose of argatroban in combination with IV r-tPA. Our aims were to test safety, develop unbiased estimates of the treatment effects, and use Bayesian analyses to estimate the probability that excellent functional recovery is increased by adjunctive low-or high-dose argatroban with r-tPA.
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Methods
Study Design and Participants
ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen
Activator for Acute Stroke) was a 3-arm, multicenter, randomized, blinded-outcome evaluation, exploratory trial performed at 16 United States and United Kingdom sites. Acute ischemic stroke patients receiving IV r-tPA within 4.5 hours of symptom onset were included if (1) age ≥18 years and (2) National Institutes of Health Stroke Scale (NIHSS) score ≥10 or any NIHSS with proximal intracranial arterial occlusion (transcranial Doppler ultrasound or computed tomography [CT] angiogram) of terminal internal carotid, middle cerebral (M1 or proximal M2), posterior cerebral (P1 or proximal P2), distal vertebral, or basilar arteries. Exclusions were planned endovascular therapy. Complete exclusion criteria is located in the online-only Data Supplement. The study was approved by each center's local review board and overseen by an independent physician safety monitor and data and safety monitoring committee. Data collection, monitoring, and analysis were performed by an independent data coordinating center.
Randomization and Blinding
Patients were randomized (1:1:1) to receive argatroban at 2 doses: low dose or high dose or r-tPA alone. Randomization was web-based and stratified using sequential minimization to balance 3 baseline characteristics: study site, presence of terminal internal carotid artery occlusion (3-level categorical variable: present, not present, or unknown), and HAT score (hemorrhage after thrombolysis). 11, 12 Treatment masking of bedside clinicians and patients was not feasible because of the complexity of sham activated partial thromboplastin time tests in a multicenter trial and the prohibitive costs of placebo manufacture and administration. Hospital clinical assessments were performed by vascular neurologists who were not blinded to treatment allocation. Neuroimaging was interpreted by a central image core blinded to randomization group and clinical outcome. Ninetyday clinical assessments were performed in person by study personnel blinded to randomization group.
Procedures
The study procedures are summarized in the online-only Data Supplement. All patients received intravenous r-tPA (0.9 mg/kg; maximum dose 90 mg, 10% administered as 1-minute bolus, the remaining infused over 1 hour) in the hospital emergency department or hyperacute stroke unit. Written informed consent from the patient or legally authorized representative was obtained. Patients randomized to argatroban received 100 μg/kg intravenous bolus over 3 to 5 minutes within 1 hour of the r-tPA bolus followed by argatroban infusion of either 1.0 μg/kg per minute (low dose) or 3.0 μg/kg per minute (high dose) for 48 hours adjusted to a target-activated partial thromboplastin time of 1.75 or 2.25×baseline (±10%) in low-and high-dose arms, respectively. Infusion rates were adjusted in response to the activated partial thromboplastin time according to a dosing algorithm 2, 6, 12, and 24 hours after initiation of argatroban; the end of argatroban infusion; and in the event of major bleeding, in which case the infusion was terminated immediately. In absence of hemorrhage, the algorithm required temporary cessation if the activated partial thromboplastin time returned >100 or >130 seconds in the low-or high-dose arm, respectively. Concomitant antithrombotics were not permitted during infusion.
Baseline examinations included routine laboratory tests, noncontrast computed tomography, vessel imaging-transcranial Doppler ultrasound or CT head±neck, if possible-NIHSS, and mRS. A repeat noncontrast CT was performed at 48 hours. Patients with baseline (pre-r-tPA) vascular imaging and no contraindication to repeat study had a 2-to 3-hour repeat study of the same modality using standard definitions of occlusion location and recanalization.
9 mRS, quality of life assessments, and NIHSS scores were obtained at 7 and 90 days. Study participants were asked at 90 days if they recalled the study treatment they had received.
Outcomes
The predefined primary outcome was the proportion of patients with a score of 0 to 1 on the mRS, indicating an excellent clinical outcome of no clinically significant residual stroke deficits at 90 (±10) days.
Secondary outcomes were sICH within 48 hours of r-tPA bolus; 2 to 3 hours recanalization; NIHSS neurological improvement at 2, 24, and 48 hours, day 7, and day 90; quality of life (standard gamble and EuroQol EQ-5D); and costs from a health system perspective. We plan to report the economic evaluation separately. Other safety outcomes included parenchymal hematoma, hemorrhagic transformation, major systemic bleeding defined as a drop in hemoglobin of ≥2 g/dL and transfusion of ≥2 U of blood.
An independent physician safety monitor and data safety board monitored the trial. sICH was defined as any evidence of bleeding on CT scan that in the opinion of the clinical investigator or independent safety monitor was associated with clinically significant neurological worsening. In the event of any neurological deterioration (NIHSS score ≥1 point increase) with any ICH, central CT/ magnetic resonance imaging findings and clinical summaries were reviewed by the physician safety monitor. To avoid abandoning a beneficial therapy based on chance findings in a small number of patients, the Data Safety Monitoring Board used a predetermined 4-stage safety algorithm. Argatroban arm termination was considered only if the lower limit of the 95% confidence interval for sICH rate exceeded an absolute rate of 10% and the Bayesian posterior probability of benefit (a minimum of 3% absolute increase in 90-day mRS score 0-1) was <20% compared with the control arm (see the online-only Data Supplement for full protocol, including the safety stopping rule).
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Statistical Analysis
The trial was designed to enroll 105 patients, with 35 patients per arm. Typical of exploratory studies, the sample size was maximized according to available trial funding and with the objective of gaining useful preliminary safety and efficacy information. Each dose of argatroban was compared with r-tPA alone and in combination (low+high argatroban+r-tPA versus r-tPA alone).
The primary clinical outcome, mRS score 0 to 1 at 90 days, was analyzed with a Bayesian Poisson regression model to generate relative risks (RRs) adjusted for stratification variables. The Bayesian approach was performed to estimate the probability of argatroban benefit compared with usual care (r-tPA alone). An RR>1 indicated the risk of an excellent clinical outcome (mRS score of 0-1) in argatroban+r-tPA. Conversely, an RR of <1 indicated worse outcomes (less patients with mRS score of 0-1). A neutral prior distribution centered at RR=1.0 was used with a 95% prior interval (PrI) of 0.33 to 3.0 (based on the largest likely effect size identified for major outcomes in randomized trials and recommended over vague or flat priors)-see the onlineonly Data Supplement for details of the Bayesian approach. 15 The same prior was used for safety termination of argatroban arms.
Stroke
June 2017
We prespecified an exploratory analysis of the primary outcome adjusting for stratification, as well as age and NIHSS. Secondary outcomes were also analyzed (adjusted for stratification variables) using the same Bayesian Poisson regression model, but with different prior distributions. Because we expected escalating doses of argatroban to likely increase the risk for sICH, we chose a skeptical prior: RR=1.5 with 95% PrI 1.16 to 2.50 for low dose and RR=2.0 with 95% PrI 1.33 to 4.0 for high dose. For sICH, an RR of >1 indicates the increased risk of sICH. Rates of arterial recanalization used a neutral prior (RR, 1.0; 95% PrI, 0.75-1.75) for both argatroban groups. NIHSS neurological improvement at 2, 24, and 48 hours used a neutral prior (RR, 1.0; 95% PrI, 0.33-3.0) for both argatroban groups. For the NIHSS at days 7 and 90, a neutral prior with wider 95% CrI (RR, 1.0; PrI, 0.25-4.0) was used for both argatroban groups. The wider PrIs reflect the increased uncertainty of treatment hazards at these later time points. Anticoagulation results, adverse event rates, and all other secondary outcomes were analyzed for treatment group differences using analysis of variance, χ 2 , and nonparametric equivalents where appropriate. Analyses were performed using intention to treat.
Four post hoc analyses (adjusted for stratification variables) were performed: (1) ordinal logistic regression of 90-day mRS outcome (scores 5 and 6 combined); (2) frequentist Poisson regression for RR and 95% CI for the primary mRS; (3) Bayesian Poisson regression using the same neutral prior as the primary outcome, and (4) sICH (intention to treat and as-treated) outcomes because 1 patient randomized to the high-dose arm never received study drug, but suffered a sICH within 45 minutes of r-tPA, using both the trial definition of sICH and the SITS-MOST (Safe Implementation of Thrombolysis in Stroke-Monitoring Study) definition (parenchymal hematoma-type 2+increase in NIHSS score ≥4 points). 16 Unadjusted RR estimates were also analyzed. We fitted all Bayesian models via Markov Chain Monte Carlo methods (online-only Data Supplement). Analyses were conducted using SAS Version 9.4 (Cary, NC) and R (v2.11.1). ARTSS-2 was preregistered with ClinicalTrials.gov, number NCT01464788.
Results
Between December 21, 2011, and March 23, 2015, 90 of 105 planned patients were randomized because the trial was stopped early after beneficial results of endovascular trials resulted in most eligible patients receiving thrombectomy, which was a study exclusion. Study patient flow diagram is shown in Figure 1A . Baseline characteristics are displayed in Table 1 . Seventy-two percent of patients were enrolled in the United States and 28% in the United Kingdom. There were minor imbalances in NIHSS, stroke onset to r-tPA, history of atrial fibrillation, and ASPECTS score (Alberta Stroke Program Early CT Score) across arms. Overall, 46 of 90 (51%) patients had baseline and follow-up intracranial arterial imaging demonstrating proximal occlusions, with the lowest percentage (11/29, 38%) in the r-tPA alone arm. Stroke pathogenesis was similar across arms (online-only Data Supplement).
Of the patients who received argatroban, 44 (73%) had it started at or before the r-tPA infusion was completed with 13±12 minutes drug overlap. The 16 (27%) remaining patients had argatroban started between 1 and 32 minutes after r-tPA infusion completion. Figure 1B and the online-only Data Supplement detail duration, infusion adjustments, and coagulation results. At 90 days, 82% of patients were unable to accurately recall their study arm and 67%, if they had received any argatroban.
Primary Outcome
The proportion of patients with an excellent clinical outcome (0-1 on the mRS) was 21% (6/29) with r-tPA alone, 30% (9/30) with low-dose argatroban, and 10/31 (32%) with high-dose argatroban (Table 2 and Figure 2A ). The single lost-to-follow-up patient's (randomized to high-dose arm) day 7 mRS score 4 was carried forward to 90 days because the local investigator confirmed that the patient had not died at 90 days. Compared with r-tPA alone, the absolute difference in excellent clinical outcomes favored argatroban: 9% (low-dose argatroban) and 11% (high-dose argatroban). Bayesian RR (95% CrI) for low, high, and either low or high dose argatroban was 1.17 (0.57-2.37), 1.27 (0.63-2.53), and 1.34 (0.68-2.76), see Table 2 . As depicted in Figure 2B , these results can be interpreted that the odds that argatroban is effective have improved from 1:1 as set in our prior (ie, the prior probability that argatroban is effective is 50%) to ≈2:1 (67% in terms of the probability) for low dose, ≈3:1 (74% in terms of the probability) for high dose, and ≈4:1 (79% in terms of the probability) for combined low+high doses.
Secondary and Safety Outcomes
Secondary outcomes are listed in Table 2 . Incidence of sICH, rates of recanalization, NIHSS improvement, and quality of life utilities were similar across study arms. Rates and types of asymptomatic ICH were comparable across arms, and no major systemic bleeding adjudicated as argatroban related occurred. A complete list of adverse events is located in the online-only Data Supplement. Mortality at 90 days occurred in 5 (17%; 95% CI, 6-36), 5 (17%; 95% CI, 6-35), and 3 (10%; 95% CI, 2-26) for r-tPA alone, low-dose argatroban, and high-dose argatroban, respectively.
Post Hoc Analyses
Results of prespecified exploratory and post hoc analyses are displayed in Table 3 . Including covariates age and NIHSS score to the primary outcome regression analysis reduced the All regression analyses adjusted for stratification variables. CI indicates confidence interval; CrI, credible interval; IQR, interquartile range; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; RR, relative risk; and r-tPA, recombinant tissue-type plasminogen activator.
point estimate and probability of treatment superiority in the high-dose arm. Frequentist RR for mRS and sICH are displayed in Table 3 and Figure 2 Ci and 2Cii. Using the SITS-MOST definition, overall rates of sICH were lower and nearly identical across arms. Substituting a neutral prior (identical to the primary outcome analysis) for the conservative, the probability that adjunctive argatroban increased sICH risk was 63%, 34%, and 48% for low, high, and low or high dose, respectively. All unadjusted outcomes are given in the online-only Data Supplement.
Discussion
ARTSS-2 is the first randomized trial of concurrent IV thrombolysis and anticoagulation. We found no evidence that the addition of argatroban increased hemorrhage or death. Moreover, the findings for the clinical outcomes were encouraging. Despite the limited number of patients studied, conservative Bayesian analyses indicated a 79% probability that adjunctive argatroban increased the percent of patients with a score of 0 to 1 on the mRS at 90 days.
Despite a paucity of events and wide 95% CIs, escalating levels of thrombin inhibition did not suggest an increased risk of symptomatic ICH. Combined with our previous study of 65 patients (mean age, 63±14; median NIHSS score, 13) treated with low-dose argatroban+r-tPA, 6 a total of 125 thrombolysed moderate-to-severe acute ischemic strokes have received adjunctive argatroban, with a total of 8 sICH (6.4%). Importantly, both studies used a conservative sICH definition that did not mandate the presence of parenchymal hematoma-type 2 or neurological worsening of ≥4 NIHSS points. Because the SITS-MOST definition of sICH accounts for the largest hemorrhage-related worsening in 90-day functional outcomes, it has increasingly become the standard used in recent stroke trials. 17 In the current study, SITS-MOST sICH incidence was the same (3.3%) in patients who received r-tPA alone compared with patients who received argatroban (as treated analysis). Combining both Figure 2 . A, Distribution of 90-day modified Rankin Scale (mRS) scores. B, Graphical depiction of Bayesian results. The neutral prior is centered at relative risk (RR) =1.0, indicating a 50:50 chance of argatroban+r-tPA superiority or inferiority. The area under the curve located on the right-hand side of RR=1.0 for each posterior represents the probability that combination is superior (ie, RR>1.0) to r-tPAalone (67%, low; 74%, high; and 79%, low+high dose). Note: the x axis is set to logarithmic scale. C, Forest plots of (i) 90-day excellent clinical outcome and (ii) symptomatic intracranial hemorrhage (sICH) within 48-hour of r-tPA, analyzed using frequentist approach and adjusted for stratification variables. CI indicates confidence interval.
adjunctive argatroban+r-tPA studies, 3 of 125 (2.4%, 95% CI by the exact Clopper-Pearson method: 0.5%-6.9%) patients who received argatroban+r-tPA suffered sICH according to SITS-MOST criteria. Our incidence is comparable to the 3.7% sICH rate reported in a recent meta-analysis of 3391 r-tPA treated strokes from 9 randomized trials. 18 Despite more severe strokes in the current study, the percentage of patients with mRS score 0 to 1 are similar to those in our previous cohort study (36%).
We used Bayesian methods to calculate estimates of the probability of adjunctive treatment benefit. 8, 9 These probabilities provide clinical investigators the best current evidence of a therapy's potential benefit and are one of the main inputs for decision-making. For example, if the posterior probability of benefit is deemed large enough, then investigators will plan a future larger trial. However, these probabilities are not obtainable from frequentist analyses. In their statement on P values, the American Statistical Association states that studies should not simply rely on a P value or statistical significance because neither is a good measure of evidence of benefit. 19 They state that where appropriate, results should be supplemented with other approaches, including Bayesian methods. These methods are uncontested for evaluation of diagnostic tests and have been recommended by the Food and Drug Administration for studies of medical devices. 20 Use of Bayesian methods in oncology 21 is widespread and have also been adopted in National Institutes of Health-funded neurological trials (with Food and Drug Administration oversight), including an interventional trial for status epilepticus. 22 Concerns about Bayesian analyses have largely been related to choosing an overly optimistic prior probability (or a prior based on weak evidence), thus, producing overly optimistic posterior probabilities of treatment benefit. This concern did not apply to this trial because we used a neutral estimate of treatment effect (RR=1.0). This use of a prior RR of 1.0 in Bayesian analyses shrinks the RR estimate at the study conclusion closer to the null, resulting in more conservative estimates of the treatment effect than with conventional frequentist estimates (online-only Data Supplement). Further, our choice of 95% PrIs for the prior allows for considerable uncertainty within a range that encompasses the RR observed for virtually all therapies between those that are beneficial (RR=0.3) or harmful (RR=3.3). 15 We analyzed outcomes using RR because its interpretation is more straightforward than odds ratios and better understood by clinicians. Moreover, odds ratio estimates in randomized trials always overestimate the point estimate for RR, and this difference becomes greater with increasing incidence of the outcome (online-only Data Supplement). The more traditional frequentist and ordinal shift results were consistent with the Bayesian.
Vessel imaging was optional to avoid delays in administering argatroban and include patients who were unable to undergo arterial imaging for various reasons (a small-bore IV, renal contraindications to iodinated contrast, lack of emergent neuroradiology interpretation, lack of support for the second imaging study, Institutional Review Board concerns, etc). Because half of the patients did not undergo arterial imaging, caution should be exercised when interpreting recanalization results.
There is strong rationale for combination medical therapy in acute ischemic stroke. Combination lytics, anticoagulants, and antiplatelets are frequently used for myocardial infarction, with demonstrable impact on reperfusion and clinical outcomes. Medical therapies are widely available and can be rapidly administered in any emergency department or stroke unit; treatment regimens are needed that reduce the frequency of reocclusion after r-tPA. Therefore, amplification and maintenance of recanalization remains a crucial target for reperfusion therapy. Despite recent important endovascular advances, a large percentage of patients remain disabled, which may be in part explained by significant delays to endovascular facilities, as well as moderately low rates of complete thrombolysis in cerebral infarction, grade 3 reperfusion. The latter may contribute to microcirculation thrombosis and no reflow that concurrent antithrombotics may prevent. Importantly, although low absolute risk (5%), new infarctions in unaffected territories are known to occur during endovascular therapy and are associated with worse patient outcomes. 23 Endovascular therapy was excluded because at the time of the trial, it was considered experimental. We feel this is an advantage of the design because it adds to the building evidence of medical adjunctive antithrombotic amplification of IV r-tPA. 6, 24 After terminating the trial at 90 patients, we tested the feasibility and explored safety and reperfusion outcomes in a small cohort treated with IV r-tPA, high-dose argatroban, and endovascular therapy in 0-to 6-hour acute ischemic stroke with large vessel occlusion. The results will be reported separately but demonstrated the feasibility and safety of combining the ARTSS-2 protocol with endovascular thrombectomy.
Study limitations include the open-label design that was necessary because of prohibitive costs of placebo manufacture and sham-activated partial thromboplastin time tests. By appointing an independent physician monitor, blinded image core, and clinical outcome evaluators, we have minimized this limitation. Given that vessel imaging was not mandatory, a meaningful analysis of early recanalization rates was not possible.
Conclusions
The results of this randomized trial, like those in our cohort study, support the safety of adjunctive argatroban in the doses assessed for ischemic stroke patients. This evidence plus our findings suggesting an increased likelihood of an excellent clinical outcome justify assessing argatroban with r-tPA in a large effectiveness trial.
